



Supplementary Materials

Amphiphilic Polypeptides Obtained by the Post-Polymerization Modification of Poly(Glutamic Acid) and Their Evaluation as Delivery Systems for Hydrophobic Drugs

Apollinaria Yu. Dzhuzha ^{1,2}, Irina I. Tarasenko ², Leonard Ionut Atanase ³, Antonina Lavrentieva ⁴ and Evgenia G. Korzhikova-Vlakh ^{2,*}

¹ Institute of Chemistry, Saint-Petersburg State University, 198504 St. Petersburg, Russia;

² Institute of Macromolecular Compounds, Russian Academy of Sciences, 199004 St. Petersburg, Russia;

³ Faculty of Dental Medicine, "Apollonia" University, 700399 Iasi, Romania;

⁴ Institute of Technical Chemistry, Gottfried-Wilhelm-Leibniz University, 30167 Hannover, Germany;

Correspondence: vlakh@hq.macro.ru (E.K.-V.)




Figure S1. SEC trace of poly(α , L -glutamic acid γ -benzyl ester). Conditions: Styragel Column, HMW6E, Waters (7.8 mm \times 300 mm, 15–20 μ m bead size), DMF containing 0.1M LiBr, 40 °C, elution rate 0.3 mL/min, refractometric detection.






Figure S2. ¹H NMR spectra of Bzl-protected (a) and deprotected (b) poly(α , L -glutamic acid) (DMSO-d₆, 25 °C): Signals (ppm): 0.80–0.85 (CH_3 , hexylamine), 1.00–1.33 (CH_2 , hexylamine), 3.5–4.5 (CH , Glu), 5.0–5.5 ($\text{O}-\text{CH}_2-\text{C}_6\text{H}_5$, Glu(OBzl)), 6.7–7.4 ($\text{O}-\text{CH}_2-\text{C}_6\text{H}_5$, Glu(OBzl)).



(a)



(b)






Figure S3. ^1H NMR spectra of P[EE(**R**(Mtr))E(H(Trt))E(**I**)E(Glc)] (a), P[EE(**O**(Boc))E(H(Trt))E(**I**)E(Glc)] (b), P[EE(**R**)E(H)E(**I**)E(Glc)] (with diffusion filter) (c), P[EE(**R**(Mtr))E(H(Trt))E(**W**(Boc))E(Glc)] (with diffusion filter) (d). Signals (ppm): 0.80-0.85 (CH_3 , hexylamine), 1.00-1.33 (CH_2 , hexylamine), 1.2-1.5 (2 CH_2 , Arg; CH_3 , Boc of Orn and Trp), 1.5-2.4 (2 CH_2 , Glu, Arg and Orn), 2.4-2.7 ($\text{CH}_3\text{-C}_6\text{H}_5$, Mtr of Arg), 2.7-3.5 (6 CH_2 , glucose; CH_2 , Orn), 3.5-4.5 (CH_2 , Glu; $\text{CH}_3\text{-O-C}_6\text{H}_5$, Arg; CH_2 , Arg, His, Orn, Trp; CH_2 , His), 6.3-7.5 (C_6H_5 , Trt of His; 2 H_2 , His; C_6H_5 , Mtr of Arg; C_6H_5 , Trp), 1.4 (CH_3 , BOC of Orn), 7.8-8.5 ($\text{NH}\text{-CO}$, all polypeptides; $\text{NH}_2\text{-C=NH}$, Arg).



(a)



(b)





Figure S4. ^1H NMR spectra (DMSO-d₆, 25 °C) of poly(α ,L-glutamic acid) modified with: (a, b) Phe (a – precursor polymer for P[EE(O)E(H)E(F)E(Glc)]; b – precursor polymer for P[EE(O)E(F)E(H₆-pept)]); (c) Phe, His(Trt) and Glc; (d) Phe, Orn(Boc), His(Trt) and Glc (with diffusion filter). Signals (ppm): 0.80–0.85 (CH_3 , hexylamine), 1.00–1.3 (CH_2 , hexylamine), 1.3–1.5 (CH_2 , Boc of Orn), 1.5–2.4 (2 CH_2 , Glu, and Orn), 2.7–3.5 (6 CH_2 , glucose; CH_2 , Orn), 3.5–4.5 (CH_2 , Glu; CH_2 , His and Orn; CH_2 , His), 6.3–7.5 (C₆H₅, Trt of His; 2 H_2 , His), 7.8–8.5 (NH-CO, all polypeptides; NH₂-C=NH, Arg).


Table S1. Composition of the amphiphilic copolymers determined by ^1H NMR spectroscopy.

Sample	Modifier				
	R or O	H	Glc	F or I	$\text{H}_6\text{-pept.}$
P[EE(O)E(H)E(F)E(Glc)]	33	26	17	10	–
P[EE(R)E(H)E(I)E(Glc)]	25	24	21	N/D	–
P[EE(O)E(H)E(I)E(Glc)]	31	24	19	N/D	–
P[EE(O)E(F)E(H ₆ -pept)]	42	–	–	26	N/D


*Side-chain amino acids and glucosamine were calculated relative to glutamic acid, taken as 100%.




(a)



(b)



(c)



(d)

Figure S5. Hydrodynamic diameter distribution measured by intensity (a,c) and by number (b,d) (DLS) for P[EE(O)E(H)E(I)E(Glc)] (a,b) and P[EE(O)E(F)E(H α -pept)] (c, d) nanoparticles.







Figure S6. Zeta-potential distribution obtained by ELS for P[EE(R)E(H)E(I)E(Glc)] (a), P[EE(O)E(H)E(I)E(Glc)] (b) and P[EE(O)E(F)E(H₆-pept)] (c) nanoparticles.




(a)



(b)




(c)




(d)


Figure S7. Hydrodynamic diameter distribution (**a-c**) and zeta-potential distribution (**d**) measured for PTX-loaded nanoparticles based on P[EE(R)E(H)E(I)E(Glc)] using: DLS by intensity (**a**), DLS by number (**b**), NTA (**c**), ELS (**d**).




(a)



(b)




(c)



(d)

Figure S8. Dose response curves illustrating the inhibition of A549 by PTX nanoformulations (**a-c**) and free PTX (**d**): PTX/ P[EE(R)E(H)E(F)E(Glc)] (**a**), PTX/ P[EE(O)E(H)E(I)E(Glc)] (**b**), PTX/ P[EE(O)E(F)E(H₆-pept)] (**c**).



(d)




Figure S9. Chromatograms of HPLC amino acid and glucosamine analysis (a-c), obtained after total acidic hydrolysis of (glycol)polypeptides: P[EE(O)E(H)E(F)E(Glc)] (a), P[EE(O)E(F)E(H₆-pept)] (b), P[EE(R)E(H)E(F)E(Glc)] (c) and calibration curves built for individual components (d).